STOCK TITAN

Biohaven Ltd - BHVN STOCK NEWS

Welcome to our dedicated news page for Biohaven (Ticker: BHVN), a resource for investors and traders seeking the latest updates and insights on Biohaven.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biohaven's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biohaven's position in the market.

Rhea-AI Summary
Biohaven announces positive biomarker data from Phase 1 EEG study of BHV-7000, confirming CNS activity and dose-dependent effects. Plans to initiate Phase 3 program in focal epilepsy by end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.36%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.36%
Tags
earnings
Rhea-AI Summary
Biohaven Ltd. announces multiple updates on key programs, including positive preliminary EEG data for BHV-7000, Phase 1 update on BHV-8000, development update on BHV-1300, and regulatory update on troriluzole. BHV-7000 shows promising results in treating epilepsy and bipolar disorder. BHV-8000 achieves projected therapeutic concentrations and is well tolerated. BHV-1300 demonstrates a competitive profile. Troriluzole Phase 3 study enrollment to be completed soon. FDA refuses to review NDA for troriluzole in SCA3, Biohaven requests Type A meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.61%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.56%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.01%
Tags
management clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.64%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
earnings
Biohaven Ltd

NYSE:BHVN

BHVN Rankings

BHVN Stock Data

4.66B
65.86M
13.63%
89.95%
10.57%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
New Haven